JP2011516588A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011516588A5 JP2011516588A5 JP2011504317A JP2011504317A JP2011516588A5 JP 2011516588 A5 JP2011516588 A5 JP 2011516588A5 JP 2011504317 A JP2011504317 A JP 2011504317A JP 2011504317 A JP2011504317 A JP 2011504317A JP 2011516588 A5 JP2011516588 A5 JP 2011516588A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- pharmaceutical composition
- parkinson
- operative
- post
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000002980 postoperative effect Effects 0.000 claims description 4
- 208000007848 Alcoholism Diseases 0.000 claims description 3
- 208000024827 Alzheimer disease Diseases 0.000 claims description 3
- 206010033799 Paralysis Diseases 0.000 claims description 3
- 208000018737 Parkinson disease Diseases 0.000 claims description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
- 230000001953 sensory effect Effects 0.000 claims description 3
- 206010003805 Autism Diseases 0.000 claims description 2
- 208000020706 Autistic disease Diseases 0.000 claims description 2
- 206010012289 Dementia Diseases 0.000 claims description 2
- 206010012335 Dependence Diseases 0.000 claims description 2
- 206010057852 Nicotine dependence Diseases 0.000 claims description 2
- 201000007930 alcohol dependence Diseases 0.000 claims description 2
- 201000010099 disease Diseases 0.000 claims description 2
- 206010015037 epilepsy Diseases 0.000 claims description 2
- 201000000980 schizophrenia Diseases 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 206010021143 Hypoxia Diseases 0.000 claims 2
- 230000004770 neurodegeneration Effects 0.000 claims 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims 2
- 206010002660 Anoxia Diseases 0.000 claims 1
- 241000976983 Anoxia Species 0.000 claims 1
- 206010003497 Asphyxia Diseases 0.000 claims 1
- 208000010496 Heart Arrest Diseases 0.000 claims 1
- 208000012902 Nervous system disease Diseases 0.000 claims 1
- 208000025966 Neurological disease Diseases 0.000 claims 1
- 230000007953 anoxia Effects 0.000 claims 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 230000001713 cholinergic effect Effects 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 230000001146 hypoxic effect Effects 0.000 claims 1
- 231100000862 numbness Toxicity 0.000 claims 1
- 235000018343 nutrient deficiency Nutrition 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 239000001301 oxygen Substances 0.000 claims 1
- 208000021090 palsy Diseases 0.000 claims 1
- 208000020016 psychiatric disease Diseases 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010029240 Neuritis Diseases 0.000 description 1
- 208000029033 Spinal Cord disease Diseases 0.000 description 1
- 206010013663 drug dependence Diseases 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 239000003176 neuroleptic agent Substances 0.000 description 1
- 230000000701 neuroleptic effect Effects 0.000 description 1
- 208000021722 neuropathic pain Diseases 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2008/002929 WO2009127218A1 (en) | 2008-04-14 | 2008-04-14 | Derivatives of galantamine as pro-drugs for the treatment of human brain diseases |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011516588A JP2011516588A (ja) | 2011-05-26 |
| JP2011516588A5 true JP2011516588A5 (enExample) | 2014-02-20 |
| JP5504253B2 JP5504253B2 (ja) | 2014-05-28 |
Family
ID=40019199
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011504317A Expired - Fee Related JP5504253B2 (ja) | 2008-04-14 | 2008-04-14 | ヒトの脳疾患の治療のためのプロドラッグとしてのガランタミン誘導体 |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP2137192B8 (enExample) |
| JP (1) | JP5504253B2 (enExample) |
| CN (1) | CN102007129B (enExample) |
| CA (1) | CA2721007C (enExample) |
| DK (1) | DK2137192T3 (enExample) |
| ES (1) | ES2463715T3 (enExample) |
| PL (1) | PL2137192T3 (enExample) |
| WO (1) | WO2009127218A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2700473T3 (es) * | 2012-07-27 | 2019-02-18 | Neurodyn Life Sciences Inc | Biodisponibilidad cerebral mejorada de galantamina mediante formulaciones seleccionadas y administración transmucosa de profármacos lipofílicos |
| PT3417862T (pt) | 2012-07-27 | 2021-08-06 | Neurodyn Life Sciences Inc | Biodisponibilidade cerebral da galantamina melhorada através de formulações selecionadas e administração transmucosal de pró-fármacos lipofílicos |
| US20170182058A1 (en) | 2014-03-25 | 2017-06-29 | Emicipi Llc | Treatment of rett syndrome |
| WO2015148487A1 (en) * | 2014-03-25 | 2015-10-01 | Synaptec Development Llc | Treatment of autism |
| US11219627B2 (en) * | 2014-05-16 | 2022-01-11 | Synaptec Development Llc | Clearance of amyloid beta |
| EP4029867A1 (en) | 2021-01-13 | 2022-07-20 | Alpha Cognition Inc. | Solid forms of galantamine benzoate gluconate |
| EP4186509A1 (en) | 2021-11-26 | 2023-05-31 | Alpha Cognition Inc. | Alpha-1062 for treating traumatic brain injury |
| US12208167B1 (en) | 2024-02-06 | 2025-01-28 | Alpha Cognition Inc. | Coated tablets for pH-dependent release of benzgalantamine |
| US12551491B1 (en) * | 2025-07-23 | 2026-02-17 | Alpha Cognition Inc. | Dosage regimens for benzgalantamine |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6150354A (en) | 1987-01-15 | 2000-11-21 | Bonnie Davis | Compounds for the treatment of Alzheimer's disease |
| JP2755403B2 (ja) | 1987-05-04 | 1998-05-20 | デイービス、ボニー | アルツハイマー病の治療のための化合物 |
| US6323196B1 (en) | 1993-10-15 | 2001-11-27 | Aventis Pharmaceuticals Inc. | Galanthamine derivatives as acetylcholinesterase inhibitors |
| US6316439B1 (en) | 1993-10-15 | 2001-11-13 | Aventis Pharamaceuticals Inc. | Galanthamine derivatives as acetylcholinesterase inhibitors |
| US6323195B1 (en) | 1993-10-15 | 2001-11-27 | Aventis Pharmaceuticals Inc. | Galanthamine derivatives as acetylcholinesterase inhibitors |
| AT403803B (de) | 1996-04-19 | 1998-05-25 | Sanochemia Ltd | Neue benzazepinderivate, diese enthaltende arzneimittel und verwendung derselben zum herstellen von arzneimitteln |
| AU1282099A (en) | 1997-10-29 | 1999-05-17 | Bonnie M. Davis | Method for treatment of disorders of attention |
| WO2000032199A1 (de) | 1998-12-01 | 2000-06-08 | Sanochemia Pharmazeutika Aktiengesellschaft | Verwendung von galanthamin und galanthaminderivaten bei akuten funktionellen hirnschäden |
| EP2311463A1 (en) | 1999-12-10 | 2011-04-20 | Bonnie M. Davis | Analogs of galanthamine and lycoramine as modulators of nicotinic receptors |
| PL202463B1 (pl) | 2000-03-31 | 2009-06-30 | Sanochemia Pharmazeutika Ag | Pochodne galantaminy, sposób ich wytwarzania, środek leczniczy zawierajacy te pochodne, zastosowanie pochodnej galantaminy do wytwarzania środków leczniczych, sposób wytwarzania środków leczniczych oraz sposób oddzielania (+)- i (-)-izomerów |
| US20030162770A1 (en) | 2002-02-22 | 2003-08-28 | Davis Bonnie M. | Use of modulators of nicotinic receptors for treatment of cognitive dysfunction |
| CN1875004B (zh) | 2003-09-26 | 2010-06-23 | 台湾神隆股份有限公司 | 那维啶酰胺衍生物的拆分 |
| AT414125B (de) | 2003-09-29 | 2006-09-15 | Sanochemia Pharmazeutika Ag | Neue derivate des 4a,5,9,10,11,12-hexahydro- benzofuro(3a,3,2)(2) benzazepin, verfahren zu deren herstellung sowie deren verwendung zur herstellung von arzneimitteln |
| EP1777222A1 (en) | 2005-09-22 | 2007-04-25 | Galantos Pharma GmbH | Cholinergic enhancers with improved blood-brain barrier permeability for the treatment of diseases accompanied by cognitive impairment |
-
2008
- 2008-04-14 CN CN200880128608.5A patent/CN102007129B/zh active Active
- 2008-04-14 PL PL08735211T patent/PL2137192T3/pl unknown
- 2008-04-14 EP EP08735211.8A patent/EP2137192B8/en active Active
- 2008-04-14 CA CA2721007A patent/CA2721007C/en active Active
- 2008-04-14 ES ES08735211.8T patent/ES2463715T3/es active Active
- 2008-04-14 JP JP2011504317A patent/JP5504253B2/ja not_active Expired - Fee Related
- 2008-04-14 WO PCT/EP2008/002929 patent/WO2009127218A1/en not_active Ceased
- 2008-04-14 DK DK08735211.8T patent/DK2137192T3/da active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007500757A5 (enExample) | ||
| UA83899C2 (uk) | Сполуки імідазолу для лікування нейродегенеративних розладів | |
| MY147442A (en) | Imidazoquinolines as lipid kinase inhibitors | |
| UA99309C2 (ru) | Замещенные пиперидинодигидротиенопиримидины | |
| JP2009506069A5 (enExample) | ||
| WO2007035348A3 (en) | Nanoparticulate aripiprazole formulations | |
| WO2008157791A3 (en) | Methods and compositions for stimulating neurogenesis and inhibiting neuronal degeneration using isothiazolopyrimidinones | |
| MX2009012163A (es) | Hetarilanilinas como moduladores para beta-amiloide. | |
| NO20092231L (no) | Arylvinylazasykloalkan-forbindelser og fremgangsmater for deres fremstilling og anvendelse derav | |
| WO2010003391A3 (en) | Anionic pregnane compounds, method for their producing and use of them | |
| TW200745135A (en) | Therapeutic agents | |
| CA2498291A1 (en) | Diazabicyclic compounds useful in the treatment of cns and other disorders | |
| JP2015524423A5 (enExample) | ||
| JP2022539152A5 (enExample) | ||
| DE60221283D1 (de) | Verwendung von oxindolderivaten zur behandlung von mit demenz in zusammenhang stehenden krankheiten, alzheimer-krankheit und mit glycogensynthasekinase-3 assoziierten leiden | |
| IL198072A0 (en) | Substituted pyrazinone derivatives for use as a medicine | |
| UA88634C2 (en) | Quaternized quinuclidine esters | |
| TW200635589A (en) | Therapeutic agents | |
| JP2011500819A5 (enExample) | ||
| RU2010114662A (ru) | Новые производные 1,4-диазабицикло(3.2.2)нонилпиримидина и их медицинское применение | |
| FR2918282B1 (fr) | Medicament pour le traitement de la maladie de parkinson | |
| WO2010019911A3 (en) | 1,4-benzoxazine compounds and derivatives thereof as therapeutic drugs for the treatment of neurodegenerative conditions | |
| TW200635906A (en) | Substituted triazolone, tetrazolone and imidazolone derivatives for use as a medicine | |
| JP2008519056A5 (enExample) | ||
| CA2511664A1 (en) | 4',4''-substituted 3.alpha.-(diphenylmethoxy)tropane analogs for treatment of mental disorders |